

Electronic Acknowledgement Receipt

EFS ID:	6912801
Application Number:	10587159
International Application Number:	
Confirmation Number:	5292
Title of Invention:	Treatment of Neurodegenerative Diseases by the Use of Gpr49
First Named Inventor/Applicant Name:	Carsten Hopf
Customer Number:	21559
Filer:	Forrester J. Liddle/Terese Miffitt
Filer Authorized By:	Forrester J. Liddle
Attorney Docket Number:	50125/113001
Receipt Date:	04-FEB-2010
Filing Date:	26-JUN-2007
Time Stamp:	14:36:15
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	778
Deposit Account	032095
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	Vassar_1999_Science.pdf	770035	no	7
			a0727ad6741e16396b9aa69adb12aed754e64235		
Warnings:					
Information:					
2	NPL Documents	Vaughan_Nat_Biotech_1996. PDF	935946	no	6
			0f3ae0bad7f6d10e4a2d64c9c618569d38c137f2		
Warnings:					
Information:					
3	NPL Documents	Vely_2000_Methods_MolBiol. pdf	422807	no	9
			2d1bebccb42a51a6eab196c96a4ae94929cea75		
Warnings:					
Information:					
4	NPL Documents	Verhoeyen_1988_Science.pdf	574584	no	3
			b73c7d88b4cc2168caeffca93e28f7596362caf6		
Warnings:					
Information:					
5	NPL Documents	Wagner_1981_PNAS.pdf	1198983	no	5
			17804cca1e6db08ae5566217dafcd718c5811033		
Warnings:					
Information:					
6	NPL Documents	Weinberger_2000_Pharmacog enomics.pdf	2121149	no	22
			0f0c37d720b6329a2caf1d2b673c6c56a3ae3104		
Warnings:					
Information:					
7	NPL Documents	Wilson_and_Nock_Curr_Opin_ Chem_Biol_2002.PDF	606670	no	5
			400878f654ad561cfa5c2be7bc4bcf8c2169c485		
Warnings:					
Information:					
8	NPL Documents	Winter_Milstein_1991_Nature. pdf	1785573	no	7
			45bfd074f034b7ec75a01bc409ae20dc2740cfb		

Warnings:					
Information:					
9	NPL Documents	Wood_1985_Nature.pdf	1209063	no	4
			578876c1bff86b8513eabc626a046eddf8af3790		
Warnings:					
Information:					
10	NPL Documents	Wu_and_Wu_J_Biol_Chem_1987.PDF	1059346	no	4
			765ba578de694fd20b61ec5cb0a6fe13720fd282		
Warnings:					
Information:					
11	NPL Documents	Xia_PNAS_1997.pdf	517114	no	6
			05f2863709a85ea9a8d83fbfa6fe2a074969e054		
Warnings:					
Information:					
12	NPL Documents	Yacyshyn_Gastroentrology_1998.PDF	1322775	no	10
			d03a2d328fb6ff7f7bf51ded38d8ba56acbe96b5		
Warnings:					
Information:					
13	NPL Documents	Yamamoto_Cell_1980.PDF	2158414	no	11
			96a2f2e876d45cdcd8d6cd88f85e81187831dd44		
Warnings:					
Information:					
14	NPL Documents	Yamamoto_2003_Hepatology.pdf	189325	no	6
			11aee965949652e89ffedb0cd3beda4cd50c828		
Warnings:					
Information:					
15	NPL Documents	Yan_1999_Nature.pdf	373337	no	5
			722fbd34827a3dcb3c13be132b81bbe8212c6e96		
Warnings:					
Information:					
16	NPL Documents	Yu_1998_J_Biol_Chem.pdf	419220	no	6
			40d3b0e6ac1d13a40d6c329e92150d316f163792		
Warnings:					
Information:					
17	NPL Documents	Yu_2000_Nature.pdf	387746	no	7
			605bfe40eab2ee840daea51aefbdf5c03c89a738		

Warnings:					
Information:					
18	NPL Documents	Yu_Cell_1994.PDF	1546380	no	13
			1e608a78871062f550f156f81f46d27730c85999		
Warnings:					
Information:					
19	NPL Documents	Zheng_Kemeny_1995_Clin_Exp_Immunol.pdf	394366	no	3
			58d93e3fc22a141d64fc69812955ec9420aadb9		
Warnings:					
Information:					
20	NPL Documents	Zon_1988_Pharma_Res.pdf	1266148	no	11
			c63c625976f649e4505ef01657aa428da2878c5c		
Warnings:					
Information:					
21	Transmittal Letter	50125_113001_Information_Disclosure_Statement.PDF	63114	no	2
			240d4024e422fc2de686c76d3e50377b413ff71c		
Warnings:					
Information:					
22	Information Disclosure Statement (IDS) Filed (SB/08)	50125_113001_1449.PDF	968946	no	13
			ec41aea8bf7bb74e185a6ace556ecd0b477d6b6e		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
23	Fee Worksheet (PTO-875)	fee-info.pdf	30223	no	2
			d716af924d296b5c24e2b205450bcbf04b284ee5		
Warnings:					
Information:					
Total Files Size (in bytes):			20321264		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.